Meteoric Biopharmaceuticals, a first-generation biopharma enterprise and a renowned name in the global bio-pharmaceutical landscape with over 100 products. The company has chalked out aggressive growth plans and is working continuously towards introducing novel, cost-effective ingredients and formulations in the biopharmaceutical space through innovative research. The company also plans to launch more concept-based finished nutraceuticals products.
Meteoric Biopharmaceuticals currently has 10 patents and over 50 trademarks to its name. It has two production area and two fully functional labs cum R&D center for a Microbiology and Enzyme Portfolio.
Commenting on company’s growth plans, Mr. Gaurav Kaushik, Managing Director & CEO – Meteoric Biopharmaceuticals, said “Our future plans include launching Synbiotics (combinations of Pre and Probitics), expanding our Probiotics & Enzymes production capacity, introducing a unique formulation for Down Syndrome and further expanding exports. Innovation and reinventing will drive our biopharma expectation and plan for years to come. Pharmacovigilance, data analysis, early detection of disease, personalised medicine – alternative medicine and expanding Biotanical extract and ways of extraction would be major focus for us. Apart from biopharmaceuticals, we are targeting more industries in the field of bio-agriculture, biosimilars, crop science, and bioenergy in the upcoming years. We have zero debt and currently spend 12% of our revenue on R&D and it has been instrumental in preparing us for the future.”
With over 100 products, Meteoric Biopharmaceuticals excels in manufacturing and marketing enzymes and enzymatic preparations, probiotics, nutraceuticals, finished formulations and animal healthcare products. A B2B company, Meteoric Biopharmaceuticals also offers product customization, concept-based formulation, and contract manufacturing under one roof. The company has over 1000 clients – both domestic as well as international across Food, Pharma, Agro, Cosmetics, Animal Healthcare, Aquaculture, Poultry, Advanced Research etc.
Speaking on the industry and expectations from the upcoming budget, Mr. Gaurav Kaushik opined, “India is on the cusp of a massive leap toward being the global biopharma leader. The industry has grown consistently both in terms of production as well as innovation. The Covid pandemic saw the Indian biopharma industry rise to the unprecedented challenge faced by the world and support it. As an industry, we are hopeful for a positive Union Budget to integrate public-private partnerships, provide an incentive for R&D, and smoothen supply chain, freight cost and logistics challenges.”
“Indian biopharma companies must ramp up new product and technology capabilities for the next phase of expansion. As learnt from the pandemic, de-risking supply chains, and manufacturing operations while expanding capacity in sensitive APIs and intermediates is critical” he added.
“This content is provided by the company and the website will not be responsible in any way for the content of this article.”